Allopurinol kinetics
- 1 May 1978
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 23 (5) , 598-605
- https://doi.org/10.1002/cpt1978235598
Abstract
A spectrophotometric assay for measuring allopurinol and oxipurinol has been developed which can detect as little as 5 × 10−8 M of each in serum and urine. With this assay, serum disappearance characteristics of intravenous and orally administered allopurinol have been investigated in man. Serum concentrations of both allopurinol and oxipurinol reach levels above 1 × 10−5 M within minutes of intravenous administration and within 1 or 2 hr of oral administration of 300 mg allopurinol. Patients receiving 300 mg allopurinol daily show a mean serum concentration of 3 × 10−5 M oxipurinol (range, 0.9 to 9 × 10−5 M). Serum half-lives of allopurinol and oxipurinol were 39 ± 11 min and 13.6 ± 2.8 hr, respectively. Estimates of renal clearance were 13.6 and 18.9 mllminfor allopurinol and 23.2 and 30.6 ml/min for oxipurinol in 2 patients studied. The metabolic conversion of allopurinol to oxipurinol in man does not appear to be altered by long-term therapy with allopurinol, which suggests that this conversion takes place by way of an enzymatic reaction not strongly inhibited by either substrate or product. These results suggest the possibility of a nonxanthine oxidase enzymatic pathway for this conversion.This publication has 10 references indexed in Scilit:
- The determination of allopurinol and oxipurinol in human plasma and urineJournal of Chromatography B: Biomedical Sciences and Applications, 1977
- Inhibition of urate production by allopurinolBiochemical Pharmacology, 1977
- Hyperphosphatemia and hypocalcemia accompanying rapid cell lysis in a patient with Burkitt's lymphoma and Burkitt cell leukemiaThe American Journal of Medicine, 1977
- Metabolism of [6-14C]allopurinol—Lack of incorporation of allopurinol into nucleic acidsBiochemical Pharmacology, 1975
- Metabolic studies of allopurinol, an inhibitor of xanthine oxidaseBiochemical Pharmacology, 1966
- Use of Allopurinol for Prevention and Control of Hyperuricemia in Patients with Neoplastic DiseaseNew England Journal of Medicine, 1966
- Allopurinol in the Treatment of GoutAnnals of Internal Medicine, 1966
- The Effectiveness of the Xanthine Oxidase Inhibitor Allopurinol in the Treatment of GoutAnnals of Internal Medicine, 1965
- Effect of allopurinol (4-Hydroxypyrazolo-(3,4-d)pyrimidine) on serum and urinary uric acid in primary and secondary goutThe American Journal of Medicine, 1964
- Uric acid excretion and renal function in the acute hyperuricemia of leukemiaThe American Journal of Medicine, 1964